Determining the Predictive Validity of 3D Models & Achieving Standardization for Preclinical Efficacy Testing
|
|
- Trevor Mitchell
- 6 years ago
- Views:
Transcription
1 Determining the Predictive Validity of 3D Models & Achieving Standardization for Preclinical Efficacy Testing August Jason Ekert, Head of Complex In Vitro Models Platform Technology and Sciences GlaxoSmithKline (GSK)
2 Overview Background on pharma industry and success rate What are the greatest opportunities and challenges in adoption of more predictive 3D models? What key components should be considered when developing a predictive 3D model? What constitutes a validated model from an industry standpoint? How do we scale and automate 3D models in preclinical drug discovery?
3 The major reasons behind failure: Efficacy and Toxicity ~5% overall drug development success rate ~90% of the overall cost for a drug approval from Phase III -> Still ~40% of Phase III trials fail Ledford H. Nature 477, (2011) Current Models: Non-humanized animal models: systemic, but not human In vitro human assays: neither organotypic nor systemic Need better predictive, more human relevant preclinical models 3D Cell Culture Draws Drug Developers Interest Genetic Engineering and Biotechnology News, September 15, 2016, Zimmermann, A
4 Convergence of multiple disciplines to develop standardized and validated models of human diseases with clinical relevance Innovative Technology ipscs, CRISPR/Cas9 Gene editing omics High content imaging Computational Modeling (i.e. Deep Learning) Bioprocessing Bioreactor Microfluidics Organs-on-chip Biofabrication Automation/Robotics 3D Bioprinting Organoid Biomaterials Tissue Engineering Regenerative Medicine Innovation brings opportunity! Current Opinion in Biotechnology, Volume 35, 2015,
5 Opportunities for more predictive models earlier in R&D Reduce/replace reductionist screening models Reduce/replace animal models Presentation title in footer 5 Marx etal 2016; Altex;33(3):
6 Opportunities for more predictive models earlier in R&D translational and predictive value of models earlier in discovery When possible, combining safety and efficacy predictive models Presentation title in footer Marx etal 2016; Altex;33(3):
7 Filling the Gaps! Game-changers in drug development: the technologies that are revolutionizing research Hesperos Printed Muscle Fibers LAB-ON-A-PRINTER TM GSK is not advocating or promoting any of these but sharing these as examples for the different technology platforms
8 Current Complex In Vitro Models Fit & Potential Impact One-two cell types Simple Structure Multicellular Complex Structures Target ID & validation (MoA) Hit/lead discovery Lead optimisation Candidate selection Preclinical safety (efficacy/moa) Clinical assessment #compounds 1000 s 100 s 10 s 1-3 Lower Throughput More complexity GSK is not advocating or promoting any of these but sharing where the companies themselves have positioned their models
9 Challenges in adoption of more predictive 3D models $$$ and timelines can determine scope of validating/qualifying new model Need to establish confidence in both specificity and sensitivity to identify relevant endpoints Need to identify value in generating critical data and specific context of use for models Fee for service vs in house implementation Target validation vs High throughput vs lead optimization (LO) Presentation title in footer 9
10 Key components that should be considered when developing a predictive 3D model scientific due diligence 1. Application of 3D model (context of use): stage of drug development level of complexity of the model adequate for the information provided 2. Platform potential 3. Clinical translatability capability determine what aspect of the disease will be recapitulated and the level of complexity required to adequately model the disease 4. Histopathological evaluation: Cell morphology and viability Cell functionality Gene expression 5. How the 3D model has been/is being validated? Presentation title 10
11 Validated model from an industry standpoint Evidence of prediction of clinical efficacy or toxicity Strong proven track record from peer-reviewed literature Human-relevant functionalities (endpoints) and bio-markers Modulate disease target or pathway Robustness and reproducibility Additional : Phenotype reversal- demonstrate that the disease phenotype can be reversed toward a healthy phenotype Presentation title in footer 11
12 Current Complex In Vitro Models Fit & Potential Impact One-two cell types Simple Structure Multicellular Complex Structures Target ID & validation (MoA) Hit/lead discovery Lead optimisation Candidate selection Preclinical safety (efficacy/moa) Clinical assessment #compounds 1000 s 100 s 10 s 1-3 Lower Throughput More complexity GSK is not advocating or promoting any of these but sharing where the companies themselves have positioned their models
13 Example of validated model for LO- lung on a chip Wyss in collaboration with GSK Recapitulating pathological changes in barrier integrity Clinical translatability LO testing Dongeun Huh et al., Sci Transl Med 2012;4:159ra147 13
14 Current Complex In Vitro Models Fit & Potential Impact One-two cell types Simple Structure Multicellular Complex Structures Target ID & validation (MoA) Hit/lead discovery Lead optimisation Candidate selection Preclinical safety (efficacy/moa) Clinical assessment #compounds 1000 s 100 s 10 s 1-3 Lower Throughput More complexity
15 Neuratect Crack-it Challenge Sponsors: GSK, Sanofi, Abbvie, BASF, NC3Rs Key Collaborators: Mimetas, Institute of Risk Assessment Sciences (IRAS; Utrecht University, Netherlands) and CDI Key Objectives: Optimise 2D- and 3D-culture of mixed neuronal subtypes using selected human ipsc-derived cell types. Morphologically- demonstrate the presence and maturity of different neuronal subtypes in 2D and in 3D cultures. Functionally- characterize using endpoints that are involved in neuronal function and toxicity using high content imaging (3D) and multi-electrode array (MEA) plates (2D). Pharmacological proof of concept- demonstrate sensitivity of selected endpoints using reference compounds in both the 3D OrganoPlates and the 2D MEA-plates. Mimetas Organoplate
16 Physiologically relevant human stem cell based model(s) to identify neurotoxicity in vitro CDI Glutaneuron(70%)/ CDI icell(15%)/ Astrocyte(15%) co-culture (75k) DIV 16 β(iii)tubulin / S100β / DAPI DIV 21 β(iii)tubulin / S100β / DAPI DIV 23 β(iii)tubulin / S100β / DAPI DIV 25 β(iii)tubulin / S100β / DAPI DIV 7 MAP2/ Synapsin-I/ DAPI DIV 5 MAP2/, vglut/ vgat / DAPI Milestones Reached: Optimal ratio for 3D culture longevity and reproducibility Prototype- ephys (MEA) and imaging readouts in the Mimetas OrganoPlate Calcium imaging
17 Current Complex In Vitro Models Fit & Potential Impact One-two cell types Simple Structure Multicellular Complex Structures Target ID & validation (MoA) Hit/lead discovery Lead optimisation Candidate selection Preclinical safety (efficacy/moa) Clinical assessment #compounds 1000 s 100 s 10 s 1-3 Lower Throughput More complexity
18 Scale and automation of 3D models Develop a flexible high-throughput 3D lung tumor model Background Tumor spheroids better model physiological organization of cells (takes cell-cell and cell-matrix interactions into account) develop flexible high throughput 3D tumor platform Small tumor filling alveolus of the lung Lung tumor spheroid Ekert etal 2014 PLoS One Mar 17;9(3):e
19 Scale and automation of 3D models Generation of HTS 3D tumor assay Cells Tumor (cell line, organoids, primary tumor) TME (CAF, endothelial, blood cells) Monotypic vs heterotypic Tissue Architecture Collagen, Matrigel Hydrogel Nanoculture plates Microfluidics Matrix-free Readouts Cell Viability Cell death, apoptosis Spheroid size, number, width Morphology Instrumentation Acumen Operetta Incucyte Envision BioMek SelecT Natasha Cover, Hai Sheng, BR assay group 19
20 3D Lung Tumor Cell Model High-throughput format of single 3D spheroid formed in each well of 96 well plates We suggest that such subtle microenvironment-induced changes in lung tumor cell physiology add a level of complexity to cell-based assays that may be more representative of the in vivo tumor microenvironment. Ekert etal 2014 PLoS One Mar 17;9(3):e
21 Development of a flexible high-throughput 3D lung tumor model Spheroid formed from lung tumor cells ULA plate Signal transduction Proliferation Migration T cell killing Compound libraries Target discovery Ekert etal 2014 PLoS One Mar 17;9(3):e92248 Target validation 21
22 Conclusions Evaluation of the predictive value of models starts with the disease No standards or thorough scientific due diligence lists/criteria for model qualification/validation Predictive / human relevant models should be used at every step of drug development The predictive value of a model is more important than cost of the model, throughput, the ease of use or the gold standard.
23 Acknowledgements GSK Complex In Vitro Models Team Gianni Dal Negro Claire Jeong Neuratect-CRACK-IT GSK- Matthew Cato and Wayne Rycroft Mimetas Jos Joore IRAS Remco Westerink CDI Giorgia Salvagiotto Thank you for your attention! Questions? contact:
Break the 3D barrier CORNING 3D CELL CULTURE
Break the 3D barrier VESSELS SURFACES MEDIA CORNING 3D CELL CULTURE Get there fast with 3D cell culture. Whether you re just getting started in 3D cell culture, looking for proven ways to scale up, or
More informationHIGH-THROUGHPUT HUMAN TISSUE AND DISEASE MODELS. Organ on a chip. Now.
HIGH-THROUGHPUT HUMAN TISSUE AND DISEASE MODELS Organ on a chip. Now. High-throughput human tissue and disease models We all want better medicines, that s obvious. To make this possible, you need better
More informationTriggering Calcium Responses in Various Human ipsc-derived Neural Cell Types. Giorgia Salvagiotto, PhD June 2016
Triggering Calcium Responses in Various Human ipsc-derived Neural Cell Types Giorgia Salvagiotto, PhD June 216 Transformative Potential of ipsc Technology: Enabling for Drug Discovery, Toxicology, and
More informationBioengineering to reduce animal use and improve drug development
Bioengineering to reduce animal use and improve drug development Anthony Holmes PhD Programme Manager Technology Development NC3Rs Institute of Bioengineering Launch Event Queen Mary, University of London
More informationOrgan on a chip: A Commercialisation Report Card Trying to make an objective assessment on the status of a new technology (and avoid the hype)
Organ on a chip: A Commercialisation Report Card Trying to make an objective assessment on the status of a new technology (and avoid the hype) Dr JM Wilkinson, Dr K Davidge Kirkstall Ltd. 06/12/2016 Content
More informationCell Health and Viability Assays Real-time automated measurements of cell health and viability inside your incubator
INCUCYTE LIVE-CELL ANALYSIS SYSTEM Cell Health and Viability Assays Real-time automated measurements of cell health and viability inside your incubator See what your cells are doing and when they do it
More informationIntroduction to Assay Development
Introduction to Assay Development A poorly designed assay can derail a drug discovery program before it gets off the ground. While traditional bench-top assays are suitable for basic research and target
More informationTECHNOLOGY READINESS LEVELS (TRLs)
TECHNOLOGY READINESS LEVELS (TRLs) Technology readiness levels (TRLs) is a measure of estimating technology maturity of core technologies in a program during the selection process and in subsequent monitoring
More informationNon-Animal Approaches - The Way Forward Multi-Organ-Chip developments: Towards a paradigm shift in drug development
Non-Animal Approaches - The Way Forward Multi-Organ-Chip developments: Towards a paradigm shift in drug development Transatlantic Think Tank on Toxicology Berlin June 2015 Biology-inspired microphysiological
More informationA GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA
A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA Découpe 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s Patient centered, translational technology
More informationNEW INSIGHTS. NEW DISCOVERIES. Real-time automated measurements of cell health, movement and function inside your incubator.
THE NEXT GENERATION HAS ARRIVED IncuCyte S3 Live-Cell Analysis System Real-time automated measurements of cell health, movement and function inside your incubator. NEW INSIGHTS. NEW DISCOVERIES. See what
More informationA gateway to academic excellence for Biotech and Pharma
A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging
More informationLabel-free, real-time live-cell assays for spheroids: IncuCyte bright-field analysis
Introduction APPLICATION NOTE IncuCyte Live-Cell Analysis System Label-free, real-time live-cell assays for spheroids: IncuCyte bright-field analysis Susana L. Alcantara, Miniver Oliver, Kalpana Patel,
More informationDe-risking preclinical assets with early human insights recent advances in human tissue and disease models
De-risking preclinical assets with early human insights recent advances in human tissue and disease models Christopher Boyer, Executive Director, Bio-Link www.bio-link.com 108 South Parade, Blackburn VIC
More informationSome challenges in the development of new toxicity assays using in vitro methods
1 Some challenges in the development of new toxicity assays using in vitro methods J Malcolm Wilkinson, CEO, Kirkstall Ltd. Quasi Vivo - saving lives through better science The challenge: long drug development
More informationNEW INSIGHTS. NEW DISCOVERIES. Real-time automated measurements of cell health, movement and function inside your incubator.
THE NEXT GENERATION HAS ARRIVED IncuCyte S3 Live-Cell Analysis System Real-time automated measurements of cell health, movement and function inside your incubator. NEW INSIGHTS. NEW DISCOVERIES. See what
More informationProgress and Future Directions in Integrated Systems Toxicology. Mary McBride Agilent Technologies
Progress and Future Directions in Integrated Systems Toxicology Mary McBride Agilent Technologies 1 Toxicity testing tools of the late 20 th century Patchwork approach to testing dates back to the 1930
More informationNanoCulture Plate. Innovative Scaffold-based 3-Dimensional Cell Culture System for Oncology Drug Discovery
NanoCulture Plate Innovative Scaffold-based 3-Dimensional Cell Culture System for Oncology Drug Discovery What is 3D Cell Culture? Three-dimensional (3D) culture is an established method to form multi-cellular
More informationIntegration of FDSS7000 into a modular robotic system for Open Innovation drug discovery
Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery José Manuel Brea & María Isabel Loza BioFarma, Santiago de Compostela DRUG DISCOVERY OPEN INNOVATION CLOSED innovation
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationRecent years have witnessed an expansion in the disciplines encompassing drug
Course overview Recent years have witnessed an expansion in the disciplines encompassing drug discovery outside the pharmaceutical industry. This is most notable with a significant number of Universities
More informationENGINEERING 3D TISSUE SYSTEMS TO BETTER MIMIC HUMAN BIOLOGY
ENGINEERING 3D TISSUE SYSTEMS TO BETTER MIMIC HUMAN BIOLOGY Matthew Gevaert, Ph.D. CEO matt.gevaert@kiyatec.com The Scientific Method is GREAT! Observation Hypothesis Test F = GMm r 2 Accept Hypothesis
More informationNew methods: miniorgans
New methods: miniorgans C. Rovida CAAT-Europe, University of Konstanz 16 maggio 2018 Parma Summer School 2018 Emerging Risks for Food Safety and Public Perception 1981 2010 www.ecopa.eu 2012 Stakeholder
More information7th Annual Shanghai Symposium on Clinical and Pharmaceutical Solutions through Analysis
Mechanistic Physiological PhysioPD Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) approach Sharan A Pagano SVP, Scientific Alliances at Rosa & Co. LLC 7th Annual Shanghai
More informationThe 3Rs: are Human Stem Cells and Organs on Chip alternatives?
The 3Rs: are Human Stem Cells and Organs on Chip alternatives? Towards precision medicine in future healthcare Christine Mummery Leiden University Medical Centre University Twente hdmt Three kinds of human
More informationChallenge 23: Retinal 3D
Challenge 23: Retinal 3D Retinal 3D: A Physiologically-Competent Human Retinal 3D Model Launch Meeting 08 September 2016 Stefan Kustermann (Roche), Phil Hewitt (Merck), Francois Pognan (Novartis) or Marianne
More informationOriGene GFC-Arrays for High-throughput Overexpression Screening of Human Gene Phenotypes
OriGene GFC-Arrays for High-throughput Overexpression Screening of Human Gene Phenotypes High-throughput Gene Function Validation Tool Introduction sirna screening libraries enable scientists to identify
More informationMPS development status, first industrial adoption and current challenges. Uwe Marx EMA
MPS development status, first industrial adoption and current challenges Uwe Marx EMA 05.10.17 t4 - Report on biology-inspired MPS Marx et al. 2016 ALTEX 33 (3) 272-321 (CC 4.0 open access) MPS experts
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationA Physiological Cell based Microchip Platform. 1
A Physiological Cell based Microchip Platform www.synvivobio.com 1 Drug Development Problem What passes here often fails here Discovery Pre clinical Clinical Trials in vitro in vivo Static Well plate Platforms
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationCan Organ-on-a-Chip Technology Really Replace Animal Testing of Drug and Chemical Safety?
1 Can Organ-on-a-Chip Technology Really Replace Animal Testing of Drug and Chemical Safety? J Malcolm Wilkinson, CEO, Kirkstall Ltd. Quasi Vivo - saving lives through better science The drug development
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationYour Power for Health. Magnetic cell culturing. The n3d approach
Magnetic cell culturing The n3d approach Greiner Bio-One GmbH November 2015 Agenda CELLSTAR cell-repellent surface for 3D cell culture Magnetic cell culturing The n3d approach Applications Products / Info
More informationDRUG DISCOVERY AND DEVELOPMENT-PRECLINICAL ASPECTS
DRUG DISCOVERY AND DEVELOPMENT-PRECLINICAL ASPECTS 4th November 2014 Biomedicine Masters Program, Lund University Wayne Russell, PhD. ZEALAND PHARMA AGENDA TODAYS TALK: - INTRODUCTION TO DRUG DISCOVERY
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationStem Cell Research: Identifying emerging high priority policy issues
The state stem cell agency Stem Cell Research: Identifying emerging high priority policy issues Ellen G. Feigal, M.D. SVP, Research and Development National Cancer Policy Summit Washington, DC November
More informationND4BB Topic 3: Discovery and development of new drugs combatting Gram-negative infections
ND4BB Topic 3: Discovery and development of new drugs combatting Gram-negative infections Rob Stavenger for EFPIA partners (AstraZeneca, Basilea, GlaxoSmithKline, & Sanofi) 17 December 2012 Antibiotic
More informationWhat IMI means for POLAND
What IMI means for POLAND Maciej Bagiński Gdansk University of Technology Deputy of Polish Delegate to IMI SRG History of calls 1 st call 15 projects (395 teams) 281 mln 2 nd call 8 projects (193 teams)
More informationOrgans on Chips: The Future of Translational Research
Organs on Chips: The Future of Translational Research KRISTIN FABRE, PHD SCIENTIFIC PROGRAM MANAGER NIH NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCE (NCATS) 1 Advancing regulatory sciences Drug
More informationCONTRACT ASSAY SERVICES CONTRACT ASSAY SERVICES FOR STEM AND PROGENITOR CELLS
CONTRACT ASSAY SERVICES CONTRACT ASSAY SERVICES FOR STEM AND PROGENITOR CELLS TABLE OF CONTENTS 3 4 5 6 7 Introduction Hematopoietic Stem and Progenitor Cell Assays Mesenchymal Stem and Progenitor Cell
More informationDeveloping a human chip based platform for repeated dose toxicity testing. Heike Walles Roland Lauster Gerd Lindner Uwe Marx
Developing a human chip based platform for repeated dose toxicity testing Heike Walles Roland Lauster Gerd Lindner Uwe Marx Repeated dose toxicity testing status quo Daily observation and sampling: hematology
More informationIntegrating Molecular Toxicology Earlier in the Drug Development Process
Integrating Molecular Toxicology Earlier in the Drug Development Process Jonathan Hitchcock Molecular Toxicology, Drug Safety R&D Pfizer Global Research & Development Sandwich, Kent UK 4.5 4.0 3.5 3.0
More informationThe importance of Characterisation in Immunotherapy Product Development. Christopher A Bravery
The importance of Characterisation in Immunotherapy Product Development Christopher A Bravery cbravery@advbiols.com 1 Introduction What should be characterised and why? Physicochemical and biological approaches
More informationStem Cell Services. Driving Innovation for Stem Cell Researchers
Driving Innovation for Stem Cell Researchers Stem Cell Services Partner with us and have access to the most advanced and comprehensive stem cell services available today. 675 W. Kendall St. Cambridge,
More informationIn Vitro Pharmacology Services
In Vitro Pharmacology Services Simplify Your Drug Discovery Workflow What s What s Inside: Inside: Why DiscoverX Services x GPCR Screening & Profiling x Kinase Screening & Profiling x Safety Screening
More informationThe NYSCF Research Institute
Regenerative Medicine Research Update Susan L. Solomon The NYSCF Research Institute New York Pharma Forum February 25, 2016 Regenerative Medicine Research Regenerative medicine uses laboratory grown human
More informationFrom Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager
From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,
More informationDeveloping Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013
Developing Targeted Stem Cell Therapeutics for Cancer Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013 The Challenge of Drug Delivery for Brain Cancer Stem Cells
More informationPreclinical development for SSc indications NO COPY. a preclinical portfolio in a perfect world. Jörg Distler
Preclinical development for SSc indications a preclinical portfolio in a perfect world Jörg Distler Department of Internal Medicine 3 and Institute for Clinical Immunology University of Erlangen-Nuremberg
More informationMODULE 3 Preclinical safety May 2016 POST-GRADUATE PROGRAMME IN PHARMACEUTICAL MEDICINE & MEDICINES DEVELOPMENT SCIENCES
MODULE 3 Preclinical safety 11-12 May 2016 POST-GRADUATE PROGRAMME IN PHARMACEUTICAL MEDICINE & MEDICINES DEVELOPMENT SCIENCES René VERLOES M.D., Ph.D., lecturer in preclinical safety of medicines VUB,
More informationNovel in vitro human model systems for immunemediated. Example: auto immune vasculitis. Anja van de Stolpe, Robert Kauffmann
Novel in vitro human model systems for immunemediated diseases Example: auto immune vasculitis Anja van de Stolpe, Robert Kauffmann Immune mediated diseases auto immune diseases The problem: The immune
More informationCorning Microplates for Microscopy and High Content Imaging. Improve results with microplates for high resolution cell imaging
Corning Microplates for Microscopy and High Content Imaging Improve results with microplates for high resolution cell imaging High Performance for Cell-based Assays Within the drug discovery process, high
More informationFDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer
FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer Yongjie Zhou, M.D., Ph.D. FDA/CBER/OCTGT/DCEPT Yongjie.zhou@fda.hhs.gov isbtc Global Regulatory Summit October 29, 2008
More informationBioprinting at the Naval Research Laboratory. Bradley Ringeisen, Ph.D. Head, Bioenergy and Biofabrication Section Chemistry Division
Bioprinting at the Naval Research Laboratory Bradley Ringeisen, Ph.D. Head, Bioenergy and Biofabrication Section Chemistry Division 1 What is bioprinting? Bioprinting is the controlled deposition of any
More informationSpecialty Lab Services. Deep science at scale
Specialty Lab Services Deep science at scale Advancing biomarker research Our broad expertise and global laboratory footprint deliver deep science at scale Specialty assays drive insight into preclinical
More informationDuncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline
R&D Strategy Bridging g the academia-industry industry yg gap Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline GSK at a glance Who we are We are a science-led global healthcare
More informationhpsc Growth Medium DXF Dr. Lorna Whyte
hpsc Growth Medium DXF Dr. Lorna Whyte 27.06.2014 Training from Heidelberg Overview Background: Stem Cells Introduction: Human Pluripotent Stem Cells (hpsc) vs. Adult Stem Cells Promise of PSC Research
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More information2017 PROGRAM Hands-On Training
- FORMAT - - REGISTRATION FEE - 2 days training From Thursday morning to Friday evening 590 euros* without VAT Lectures Thursday morning Laboratory practices Rest of the time Training certificate can be
More information"Stratification biomarkers in personalised medicine"
1/12 2/12 SUMMARY REPORT "Stratification biomarkers in personalised medicine" Workshop to clarify the scope for stratification biomarkers and to identify bottlenecks in the discovery and the use of such
More informationSeevix s SVXgro: A Spidersilk Scaffold for Tissue Engineering
Seevix s gro: A Spidersilk Scaffold for Tissue Engineering Spider dragline silk exhibits extraordinary mechanical properties that combine strength with elasticity, resulting in a toughness exceeding that
More informationThe Big Picture of FTD Research: Funding, Collaboration and the Scoop on Participation
The Big Picture of FTD Research: Funding, Collaboration and the Scoop on Participation 1 st Annual FTD Caregiver Conference Raleigh, NC July 12, 2011 Our objectives today Snapshot of medical research process
More informationHuman ips/es Cell Technology and Its Application to Toxicology Testing
Human ips/es Cell Technology and Its Application to Toxicology Testing -Especially focusing on in vitro cardiac function toxicity- Atsushi Sanbuissho, PhD Daiichi Sankyo Co., Ltd. Kenji Yasuda, Prof Tokyo
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More informationOpportunities and Challenges for Manufacturing Scale Up of CAR T Cells. Mark Dudley Institute of Medicine March 1, 2016
Opportunities and Challenges for Manufacturing Scale Up of CAR T Cells Mark Dudley Institute of Medicine March 1, 2016 Disclaimer This document represents proposals for discussion by Management. Strategies/Concepts/Projects
More informationPersonalized Healthcare Diagnostik und Therapie aus einer Hand
Personalized Healthcare Diagnostik und Therapie aus einer Hand Priv.-Doz. Dr. med. Christian Meisel DVFA Life Science Conference, 17 June 2009 1 The Challenge Personalised healthcare Roche s unique position
More informationSecuring the Safety of Cell Therapies to Realize their Potential
Securing the Safety of Cell Therapies to Realize their Potential Identify and Optimize Novel Technology to Evaluate Cell Therapy Safety, Mode of Action and Efficacy. HESI Annual Meeting June 10, 2015 Presenters
More information10:10-10:22. YIA-1 A study of newly established human peripheral blood monocyte-derived ips cell line used in allergy research 10:22-10:32
10:10-10:22 YIA-1 A study of newly established human peripheral blood monocyte-derived ips cell line used in allergy research 10:22-10:32 EPA-1 Integration of conventional cell viability assays- recruiting
More informationORGAN FUNCTION ON-A-CHIP: TOWARDS NOVEL TRANSLATIONAL IN VITRO MODELS FOR HEALTHY AND DISEASED LIVER AND GUT. Evita van de Steeg, PhD
ORGAN FUNCTION ON-A-CHIP: TOWARDS NOVEL TRANSLATIONAL IN VITRO MODELS FOR HEALTHY AND DISEASED LIVER AND GUT Evita van de Steeg, PhD IMAGINE..A WORLD OF PERSONALIZED THERAPY CURRENT DRUG DEVELOPMENT PIPELINE
More informationHigh content imaging and applications
High content imaging and applications Nick Dolman Ph.D. Senior Staff Scientist Biosciences Division- Thermo Fisher Scientific For Research Use Only. Not for use in diagnostic procedures. The world leader
More informationOrgan-On-A-Chip Technologies (OOAC): Current status and translatability of data
1 Organ-On-A-Chip Technologies (OOAC): Current status and translatability of data Report produced in association with: Summaries and conclusions of a workshop debate in May 2018 between experts from industry,
More informationA Workflow to Characterize and Benchmark Human Induced Pluripotent Stem Cells Using the Operetta High-Content Screening System
CASE STUDY High-Content Analysis A Workflow to Characterize and Benchmark Human Induced Pluripotent Stem Cells Using the Operetta High-Content Screening System Human induced pluripotent stem cells (ipscs)
More informationWeek 1: Discovery Biology Basic knowledge and tools used in Research and Development
Downing - Keio Summer School 2018 Healthcare and Biotechnology Course Outline page 1 Strand A: Healthcare and Biotechnology Course Outline This course aims to provide an overview of the current challenges
More informationLes Biomarqueurs: une composante essentielle de la Recherche Translationnelle
Les Biomarqueurs: une composante essentielle de la Recherche Translationnelle Jesús Benavides Ancien Directeur de la Recherche Maladies Neurologiques. Sanofi Ecole Doctorale Biosigne. Université Paris
More informationApplications and Development of Organotypic Skin Cultures
Applications and Development of Organotypic Skin Cultures SILVYA STUCHI MARIA-ENGLER CLINICAL CHEMISTRY AND TOXICOLOGY DEPT SCHOOL OF PHARMACEUTICAL SCIENCES UNIVERSITY OF SÃO PAULO Overview Failings of
More informationWorld Stem Cells & Regenerative Medicine Congress London May 9 th -11 th, 2011
World Stem Cells & Regenerative Medicine Congress London May 9 th -11 th, 2011 Exploitation of Stem Cell Assays in Predictive Toxicology: Key Considerations Frank W Bonner Outline What are the important
More informationBayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms
Bayer Pharma s High Tech Platform integrates technology experts worldwide establishing one of the leading drug discovery research platforms Genomics Bioinformatics HTS Combinatorial chemistry Protein drugs
More informationChanging the Shape of Medical Research and Practice
Changing the Shape of Medical Research and Practice Keith Murphy Chief Executive Officer Copyright 2014, Organovo Holdings, Inc. This report is solely for the use of intended audience. No part of it may
More informationExpression Profiling for
RNAi Screen, NGS and Expression Profiling for Biomarker Discovery Namjin Chung Applied Genomics Bristol-Myers Squibb 2012 DOT Oct 2, 2012 Boston, MA Pharmacogenomics Study of the role of inheritance in
More informationForthcoming Calls for Proposals (10/11) Barcelona 28 June 2013
Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013 Indicative list Proposed topic /11 /11 /11 Identification and validation of innovative clinical endpoints for Osteoarthritis European genotype-phenotype
More informationOutcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL
Outcomes in Mesenchymal Stem Cell Manufacturing Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL Background HCTL established in 1992 to support BMT programs of Mayo
More informationCombining Target-Based and Phenotypic Discovery Assays for Drug Repurposing. Sharlene Velichko, Ph.D. Director of Research Biology November 11, 2017
Combining Target-Based and Phenotypic Discovery Assays for Drug Repurposing Sharlene Velichko, Ph.D. Director of Research Biology November 11, 2017 1 Drug Repurposing Finding new life for old drugs Initial
More informationCMC Considerations for Stem Cell-based. Donald W. Fink, Jr., Ph.D.
Food and Drug Administration Center for Biologics Evaluation and Research CMC Considerations for Stem Cell-based Products Donald W. Fink, Jr., Ph.D. Phone: (301) 827-5153 E-Mail: donald.fink@fda.hhs.gov
More informationRespiratory (tract) cell line
Respiratory (tract) cell line 25th April 2007 in TTS in Antalya Kazuhiro Ito NHLI, Imperial College, UK Translational Research In vivo In vitro Patient Healthy Volunteer Animal model Primary cells Cell
More informationChagas Disease Drug Discovery Entering a New Era. Eric Chatelain, PhD Head of Drug Discovery
Chagas Disease Drug Discovery Entering a New Era Eric Chatelain, PhD Head of Drug Discovery ICOPA Meeting, Mexico, 12 th August 2014 Chagas Disease Effective immune responses provide control of the infection
More informationWhy Doing Live-Cell Imaging?
Why Doing Live-Cell Imaging? The Snapshot Bias Different Endpoint = Different Result IncuCyte System Key Advantages IncuCyte Live-Cell Imaging System Software Advantage: Distributed Access NETWORK Unlimited
More informationNext Generation of Electronic Translational Safety NexGETS. Francois Pognan & Thomas Steger-Hartman IMI webinar
Next Generation of Electronic Translational Safety NexGETS Francois Pognan & Thomas Steger-Hartman 18.04.2016 IMI webinar Objectives of the full project Development of an infrastructure for preclinical
More informationCell Processing Workstation. In Situ Laser-Mediated Cell Purification and Processing
LEAP Cell Processing Workstation Cell Processing Workstation In Situ Laser-Mediated Cell Purification and Processing Expanding the Capabilities of Cell Processing Consistent, High-Yield, High-Purity Processing
More informationRaising the Bar in Preclinical Imaging
1 sur 5 30/03/2016 11:19 Send to printer» Feature Articles : Nov 1, 2013 (Vol. 33, No. 19) Raising the Bar in Preclinical Imaging MaryAnn Labant Preclinical imaging focuses predominantly on estimating
More informationBiological Warfare Defense at DARPA Program Overview
Biological Warfare Defense at DARPA Program Overview Stephen S. Morse, Ph.D. DARPA/ smorse@darpa.mil DARPA BWD Program (including novel or bioengineered pathogens) DARPA BWD Program (most current techniques
More informationDrug Discovery Toxicology Webinar
1 2012 2013 Vertex Pharmaceuticals Incorporated Drug Discovery Toxicology Webinar Brandon Jeffy, Ph.D., DABT Toxicologist, Discovery and Investigative Fellow Vertex Pharmaceuticals, San Diego Site 05 APR
More informationSubcommittee on Distinguishing Adverse from Non-Adverse and Adaptive Effects
Subcommittee on Distinguishing Adverse from Non-Adverse and Adaptive Effects DOUGLAS A. KELLER, PhD (sanofi-aventis US) Subcommittee Co-Chair HESI Annual Meeting Reston, VA May 13, 2010 1 The issue Advances
More information3D Cell Culture Product Intro. Bio-Byblos Biomedical
3D Cell Culture Product Intro Bio-Byblos Biomedical Rundown Product Intro Cellusponge Series Go Matrix Applications Upcoming Products Degradable series Cellusponge CB series Cell Alignment plate Vivoalign
More informationThe Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis
The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis Christelle Pythoud, PhD 2 nd EBF YSS, Barcelona Spain Celerion Switzerland
More informationImpurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA
Overview of exploratory INDs Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA July, 15 16, 2008 David Jacobson-Kram, Ph.D. DABT Office of New Drugs Center for Drug Evaluation
More informationUnderstanding brain diseases from stem cells to clinical trials
Understanding brain diseases from stem cells to clinical trials Alan Mackay Sim Griffith Institute for Drug Discovery Griffith University Brisbane, QLD Making ES cells Fertilise an egg Put in a dish Embryonic
More informationMyelin Repair Foundation Research Progress Report June 2006-July 2007
Myelin Repair Foundation Research Progress Report June 2006-July 2007 In July 2004, the Myelin Repair Foundation initiated a five-year research plan with the mission of discovering and validating new therapeutic
More information